Recent efforts to elucidate the scientific validity of animal-based drug tests by the pharmaceutical industry, pro-testing lobby groups, and animal welfare organisations by Bailey, Jarrod
WellBeing International 
WBI Studies Repository 
3-1-2019 
Recent efforts to elucidate the scientific validity of animal-based 
drug tests by the pharmaceutical industry, pro-testing lobby 
groups, and animal welfare organisations 
Jarrod Bailey 
Cruelty Free International 
Follow this and additional works at: https://www.wellbeingintlstudiesrepository.org/valaexp 
 Part of the Animal Experimentation and Research Commons, Animal Studies Commons, and the 
Design of Experiments and Sample Surveys Commons 
Recommended Citation 
Bailey, J., & Balls, M. (2019). Recent efforts to elucidate the scientific validity of animal-based drug tests 
by the pharmaceutical industry, pro-testing lobby groups, and animal welfare organisations. BMC medical 
ethics, 20(1), 16. 
This material is brought to you for free and open access 
by WellBeing International. It has been accepted for 
inclusion by an authorized administrator of the WBI 
Studies Repository. For more information, please contact 
wbisr-info@wellbeingintl.org. 
DEBATE Open Access
Recent efforts to elucidate the scientific
validity of animal-based drug tests by
the pharmaceutical industry, pro-testing
lobby groups, and animal welfare
organisations
Jarrod Bailey1* and Michael Balls2
Abstract
Background: Even after several decades of human drug development, there remains an absence of published,
substantial, comprehensive data to validate the use of animals in preclinical drug testing, and to point to their
predictive nature with regard to human safety/toxicity and efficacy. Two recent papers, authored by pharmaceutical
industry scientists, added to the few substantive publications that exist. In this brief article, we discuss both these
papers, as well as our own series of three papers on the subject, and also various views and criticisms of lobby
groups that advocate the animal testing of new drugs.
Main text: We argue that there still remains no published evidence to support the current regulatory paradigm of
animal testing in supporting safe entry to clinical trials. In fact, the data in these recent studies, as well as in our
own studies, support the contention that tests on rodents, dogs and monkeys provide next to no evidential weight
to the probability of there being a lack of human toxicity, when there is no apparent toxicity in the animals.
Conclusion: Based on these data, and in particular on this finding, it must be concluded that animal drug tests are
therefore not fit for their stated purpose. At the very least, it is now incumbent on—and we very much encourage—the
pharmaceutical industry and its regulators to commission, conduct and/or facilitate further independent studies involving
the use of substantial proprietary data.
Keywords: Animal testing, Translational, Nonclinical, Clinical, Safety, Concordance
Background
Animal testing has been central to pre-clinical drug de-
velopment for several decades, yet there remains no sub-
stantial, robust, published evidence that this has a
scientific basis—i.e. that these tests are reliably predictive
of human responses, both with respect to efficacy and
toxicity/safety. With specific regard to toxicity, there are
some analyses in the scientific literature (see, for ex-
ample, [1–8]), but these are relatively few and limited,
and with caveats: this must be considered perplexing,
given the controversial nature of animal tests from an
ethical perspective, and it also impacts significantly on
human health and wellbeing.
Because of this, in 2013, we authored the first of a series
of three papers (published in 2013–2015), which analysed
publicly-available toxicity data on the use of animals in
testing new drugs intended for human use [9–11]. These
studies were ground-breaking, in that — in the face of a
paucity of similar analyses (certainly comprehensive, ro-
bust and statistically appropriate ones) by the pharmaceut-
ical industry — they constituted, to our knowledge, the
most comprehensive published analyses of this kind to
date, based on the largest database of animal and human
toxicity studies yet compiled.* Correspondence: Jarrod.bailey@crueltyfreeinternational.org
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Briefly, we concluded, based on our thorough analyses
that used the most-appropriate statistical methods, that
the preclinical testing of pharmaceuticals in animals
could not be justified on scientific grounds, as well as on
ethical grounds. This position was based on the salient
finding that the absence of toxicity in animals (dogs, rats,
mice and rabbits and monkeys) provides essentially no
insight into the likelihood of a similar lack of toxicity in
humans: the former contributes no, or almost no, evidential
weight in relation to the latter. Quantitatively, if, for ex-
ample, a new drug has (based on prior information, such as
similarity to other drugs, data from in vitro or in silico tests,
and so on) a 70% chance of not being toxic in humans, then
a negative test in any of these five species will increase this
probability to an average of just 74%. The most controver-
sial species, dogs and monkeys— the use of which, as opin-
ion polls show, the general public object to particularly
strongly — were the least predictive for humans in this re-
spect, raising the probability from 70% to just 72 and 70.4%
respectively. Therefore, animal tests provide essentially no
additional confidence in the outcome for humans, but at a
great ethical, and financial, cost.
Main text
Responses to our analyses of animal drug/toxicology
tests, and continued defence of animal drug testing
Following the publication of each of our three, comple-
mentary papers in 2013, 2014 and 2015, we wrote to
dozens of representatives of pharmaceutical companies,
regulators and other stakeholders, requesting feedback,
thereby hoping to build on our work and open some
dialogue on this important issue, with ethical implica-
tions for the animals used, as well as for human users of
pharmaceuticals. Disappointingly, only scant responses
were received, and almost all of them were formulaic,
and polite, but not engaging. The Association of the
British Pharmaceutical Industry (ABPI) voiced some
concerns over various attributes of the data set we used
[12], but our substantial, published response constituted
a full rebuttal [13]. Perhaps belatedly, the UK’s National
Centre for the 3Rs (NC3Rs)—despite its initially dismis-
sive stance—announced in the summer of 2016 its own
collaborative project with the ABPI, to analyse industry
data [14] We naturally welcome this, providing, of course,
that it is done transparently and objectively, and preferably
with independent oversight. Its eagerly-awaited report
was expected in late 2018, but still has not been an-
nounced at the time of writing.
In the meantime, some advocates of animal drug-tests
have continued to argue that these tests have utility, by
citing some of the few, previous reports suggesting that
this might be the case. This must be addressed, because
this conclusion is not supported by those papers. One of
these reports [2], as we have already discussed in our
work, did not estimate specificity, without which the evi-
dential weight toward likelihood of human toxicity/
non-toxicity provided by the animal models—which is
precisely what we need to know—cannot be calculated.
As the authors of the cited study themselves acknowl-
edged, “A more complete evaluation of this predictivity
aspect will be an important part of a future prospective
survey.” Another such cited report [15] showed human
predictability for some therapeutic areas to be over
90%—yet it also showed many other areas where results
from animal studies failed to significantly correlate with
human observations, which were overlooked. Import-
antly, this analysis also utilised Likelihood Ratios (LRs),
and the author argued why this is superior and neces-
sary— much as we did in our own papers. Our rationale
for using LRs—in place at the inception of our analyses,
before any data were analysed, and in common with the
aforementioned study—was, simply, because LRs are
much more appropriate and inclusive, incorporating
sensitivity and specificity, both of which are necessary to
derive the true value of the results of any test, and which
are superior to Predictive Values (PVs), because they do
not depend on the prevalence of adverse effects. We dis-
cussed this in detail in our papers, and others have spe-
cifically supported this approach [16].
Other, recent published analyses of drug toxicology data
Two studies similar to our own have been published in
the past year. Given our interest in this, and given the eth-
ical and scientific importance of the issue, we wish to add
to the discussion and debate, by highlighting areas with
which we agree and that we welcome, but also some issues
we have with those papers and their conclusions.
Monticello et al.
A study not limited to, but relying on, PVs was very re-
cently published by Monticello et al. in November 2017
[17]. While we welcome and appreciate the authors’ at-
tempts to elucidate this controversial and opaque issue,
we believe their conclusion that, “These results support
the current regulatory paradigm of animal testing in
supporting safe entry to clinical trials and provide con-
text for emerging alternate models”, must be addressed.
In our opinion, there are several important caveats.
Perhaps the most salient is that—while the authors re-
port both PVs and LRs—they focus almost exclusively
on Negative Predictive Value (NPV) to support their
conclusion. This is puzzling, given the nature of these
statistical metrics and their associated qualities and
shortcomings, and especially so, given that the authors
specifically discuss some of them before ultimately over-
looking them. For instance, even though they admit that
LRs “are not influenced by clinical positive prevalence”
(which is why, some assert, they may be superior), this
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doesn’t prevent the authors going on to concentrate on
the PVs, which are influenced by toxicity prevalence.
We, in our analyses, argued, in some detail, why LRs
should be used in preference to PVs [9–11, 13], as men-
tioned above. There is plentiful support for this in the
literature. In brief, experts assert that LRs are the “opti-
mal choice”, are “more informative than PVs”, and are
“the single most powerful indicator of diagnostic useful-
ness”, as they incorporate sensitivity and specificity, and
are independent of prevalence, which must be taken into
account to estimate the value of a test (see [18–24]).
Monticello et al.’s emphasis on a high NPV is accepted
to be “…largely based on the low clinical positive preva-
lence observed in our database and in the literature,
which can be attributed to the fact that compounds en-
tering clinical development have typically cleared many
safety hurdles via extensive in silico, in vitro, and in vivo
lead optimization screening activities.” Yet, it seems that
the authors overlook the contribution of these screening
activities, when they conclude that it is not they, but the
lack of toxicity in animal tests, which predicts a lack of
toxicity clinically, to the degree that they support the
current paradigm centred on animal testing. What also
challenges their conclusion—even taking the authors’
stance and sidestepping the LRs to concentrate on the
PVs—is that their calculated Positive PVs (PPVs) were rela-
tively low (a reported mean of just 36%, even when the
low-scoring ‘other’ organ category was excluded); the au-
thors chose to report that there were two impressive values
out of the 36 reported, for non-human primates (NHPs), in
the nervous system and gastrointestinal categories. We
must question how this can “support the current regulatory
paradigm of animal testing”. Animal tests aren’t just pur-
ported to exist to “support safe entry to clinical trials” by
predicting which drugs might not be toxic to humans—they
are also purported to serve as an efficient means of detect-
ing which drugs might be harmful.
When one examines the LRs in Monticello et al.’s ana-
lysis instead of the PVs (see our argument above), a
clearer picture emerges. The reported inverse Negative
LRs (iNLRs) are very low indeed—sometimes less than
1.0, and often barely greater than unity—which suggests
that the animal tests are providing no evidential weight
to the probability that a drug will show no toxicity in
humans. This is precisely the salient finding we reported
in our papers [9–11], and which underpins our argu-
ment that the animal tests are not fit for purpose. They
report a mean iNLR of just 1.5–1.6, and a mean Positive
LR (PLR) of 2.9. These are low LR values, which indicate
that very little evidential weight is being provided by the
animal tests to the probability of human toxicity/absence
of toxicity. They also report similarly poor iNLRs for ro-
dents, dogs and monkeys, as we found. In short, in many
ways, they actually repeat and reinforce our findings, in
accordance with their statement in section 2.7 of their
Methods, that, “As a general rule, a test is considered
‘diagnostic’ in predicting a positive outcome when the
LR+ is >10 or for predicting a negative outcome when
the iLR- is > 10.” Of their 36 possible results, only two
PLRs/LR+ met the authors’ acknowledged ‘diagnostic’
definition of a value of > = 10, and none of the iNLRs/
iLR- did so. In fact, 30 of the iLR- values were < =2, with
most of these in or around unity; i.e. they provided no
evidential weight at all. In other words, by the definition
and criteria that they cite, the animal tests, based on
their data and their analysis, cannot be considered to be
diagnostic/predictive.
We appreciate that the authors acknowledge some im-
portant points about this area of science generally, as
well as some limitations of their study. As we did in our
own work, they report “limited” efforts to analyse the
value of animal tests in the past, and accept they are
based on “historical precedence” and an assumption of
value. With regard to their analysis, they accept that
their data involved just 182 drugs (compared to our >
3200, for example); they looked only at animal test/
Phase I concordance, and didn’t include later phase clin-
ical trials, in which more drugs will fail. Their study also
used few, broad categories for adverse drug reactions
(ADRs), which favours their hypothesis compared to
more, and more stringent, classifications; and they com-
bined mice and rats as ‘one effective species’, even
though mice and rats often show significant differences
in toxicity [11]. Finally, they reported no conflicts of
interest, but thanked almost 20 biopharmaceutical com-
panies in their acknowledgements, and have affiliations
to nine companies. While we do not suggest any impro-
priety, some might argue that they could have an inter-
est in justifying their industry’s and companies’ historic
and current use of animals in drug testing.
Clark and Steger-Hartmann
This was an analysis of more than 3000 drugs, based on
data in Elsevier’s comprehensive PharmaPendium data-
base [25, 26]. The authors took a similar approach to
our own, by using LRs to determine the diagnostic
power of tests in animals to inform human toxicity, as
well as concluding that their study confirmed our own
salient finding: “…the lack of these [adverse] events in
nonclinical [animal] studies was found to not be a good
predictor of safety in humans, thus partly confirming the
findings of Bailey et al. (2014). [citing one of our series
of three papers]”.
Confirmation of our salient finding is of the utmost
importance for two reasons. First, though we sought no
validation of our own approach and publications, but
have always had the utmost confidence in them, some
stakeholders with opposing opinions on the value of
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animal-based drug testing were intent on denigrating
our work. Secondly, no matter how well any animal test
might predict human toxicity (hypothetically), it is the
absence of toxicity in animals that is the critical factor
for the progression of a new drug into clinical (human)
trials. As we continue to argue, if animal tests fail in this
crucial respect—as they appear to do—this not only
means those tests are not fit for their overall purpose
(identifying safe and effective human drugs), but this must
have repercussions for the pharmaceutical industry and its
regulators, and how they approach drug testing generally.
This paper also confirmed our other main finding,
which suggested that adverse reactions in animal tests are,
in fact, also likely to occur in humans (though, import-
antly, often not in a similar manner). Crucially, however,
we have interpreted the consequences of this aspect differ-
ently. Both the authors of this paper, and ourselves, found
this aspect to be very variable, with no clear pattern in
terms of types of toxic effects or types of drugs. We there-
fore concluded that this cannot be considered particularly
relevant or reliable. Clark and Steger-Hartmann, however,
provided some examples of where animals did predict hu-
man toxicity, but did not show, or weigh these against,
areas where this predictive aspect was lower, non-existent,
or negative. Indeed, some of the examples they provided
were only just over the statistical threshold they had them-
selves had set. Consequently, we believe that while both
their data and our own data support their conclusion that,
“The animal-human translation of many key observations
is confirmed as being predictive”, they do not support
their conclusion that their study “…confirmed the general
predictivity of animal safety observations for humans”.
This is compounded by very poorly predictive observa-
tions that can only be considered as serious, such as death,
convulsions, movement disorders and liver disorders.
Conclusions
The first salient point must be this: to determine the evi-
dential weight provided by animal tests to the probability
of human toxicity/non-toxicity of new drugs—which is
the specific question that must be asked to determine
the scientific value of these tests—it is LRs that must be
used as the statistical metric, not PVs. We made the case
for this in the series of three papers describing our own
studies, and, prior to, and during, our analyses, we
sought the advice of two professional and eminent Euro-
pean statisticians, and an experienced pharmaceutical
consultant au fait with the matter [16], who concurred.
We acknowledge that all statistical approaches have their
advantages and disadvantages, and multiple approaches can
be informative. Further, we appreciate that more-complex
Bayesian modelling may be required to gain further insight
into the matter in the future, for instance, in addition to
fuller harm–benefit analyses and looking into specific
pharmaceutical and toxicological areas. However, we be-
lieve that the evidence shows—as we mentioned above—
that LRs are more informative, inclusive and valuable than
PVs, at least when used on their own and as a first step in
gauging how predictive animal testing might be for human
toxicity [18–24].
This has not prevented some individuals/groups who
defend animal-based drug testing from focusing on PVs
and overlooking LRs, and, perhaps more seriously, omit-
ting mention of the most conspicuous and pivotal find-
ing of our studies. That is the second salient point,
which is that the absence of toxicity in animals provides
essentially no insight into the likelihood of a similar lack
of toxicity in humans. As the absence of toxicity in ani-
mals is the critical factor for the progression of a new
drug into clinical trials, this has extremely important im-
plications for drug development and safety. Our analyses
indicate that, if a drug appears safe in animals, it could
very well still be toxic in humans. Thus, any claim that
animal safety tests do a “good job” of predicting drug
safety profiles, is without foundation. This has serious
ethical implications that are of interest to the readers of
this journal. Millions of animals are used in drug testing
every year around the world, which can entail severe suf-
fering, pain and death, which most people (at least in
the UK, EU and USA) oppose, regardless of human
benefit [27–31]. Suffering in animal drug testing is often
severe and prolonged: animals used in chronic toxicity
and carcinogenicity studies, for instance, receive the test
substance at high doses, daily, seven days a week, for
two years with no recovery periods [32], and The Organ-
isation for Economic Co-operation and Development
(OECD) [33] and the Nuffield Council on Bioethics [34]
list the following as common conditions and clinical
signs that may occur during such tests, which indicate
that an animal is experiencing pain and/or distress, and
suffering: Gasping, difficulty breathing, excess salivation
and nasal discharge, tremor, changes in blood pressure,
seizures, convulsions, coma, abnormal vocalization, ag-
gression, diarrhoea, vomiting, bleeding from any orifice,
oedema, abdominal rigidity, rectal or vaginal prolapse,
swollen joints, and paralysis.
In addition, there are human ethical consequences. If
animal testing of proposed new human drugs is not suf-
ficiently predictive of human safety—or, as we argue at
least in some respects, not predictive at all—then there
is significant human suffering, pain and death, too, as
science and drug development are not serving human
drug users and sick people who are depending on the
best science being conducted to develop much needed
new drugs that are safe and effective. Drugs appearing to
have no serious toxicity may go on to cause human harm
either in clinical trials or, even worse, if they pass through
clinical trials involving relatively limited numbers of
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people, are of limited duration and involve limited lifestyle
circumstances and factors, and make it to market where
they reach millions of users and may have to be with-
drawn when their toxicity to humans is recognised. It is
also acknowledged that drugs appearing to have serious
toxicity in animal tests will not proceed to human trials,
so drugs that may have been safe and effective in humans
will have been lost.
We reiterate that we welcome any objective efforts to
shed light on the value—or lack of value—of animal tests
for drugs intended for human use. However, for all the
reasons outlined above, we must contend that the two
most recent publications discussed, while they have
much merit, do not, as their authors conclude, “…sup-
port the current regulatory paradigm of animal testing
in supporting safe entry to clinical trials and provide
context for emerging alternate models” [17], or “con-
firm[ed] the general predictivity of animal safety obser-
vations for humans” [26].
In any case, prima facie, it seems clear that there is
something gravely wrong with the way in which drugs are
developed and tested: more than 90% of the drugs that ap-
peared to be safe and effective in animals went on to fail
in human trials between 2006 and 2015 [35, 36]. It has
been claimed that this simply is ‘a reflection of normal de-
sign process’, but would this failure rate be thus described
and acceptable for aeroplanes, car brakes, or nuclear
power stations? When this process is putting people at
risk—as is the case in drug development—this excuse can-
not be valid. It is claimed that the absence of thousands of
human deaths in Phase I clinical trials illustrates that ani-
mal testing is fit for purpose, yet this overlooks the pre-
cautionary and carefully monitored nature of these trials,
which involve few individuals (typically 6–12), and the ad-
ministration of small doses. Therefore, the fact that any
unexpected deaths have occurred in Phase I trials may be
considered alarming, but examples include: the TGN1412
(Northwick Park) trial in 2006 [37–42]; several deaths in a
hepatitis drug trial (fialuridine) in 1993 [43, 44]; and Bial’s
BIA 10–2474, which killed and hospitalised (via cerebral
micro-bleeds) clinical trial volunteers [45–47]. It was sub-
sequently shown that non-animal tests could, and would,
have detected these events, at least for TGN1412 [48, 49],
fialuridine [50] and BIA 10–2474 [51], if they had been
more widely used. In 2016, five unexpected deaths were
reported of cancer patients in a CAR-T immunotherapy
trial for Juno Therapeutics, attributed at the time to an inter-
action between genetically-engineered cells being infused
into the patients and a co-administered chemotherapy drug.
[52] A study of US Food and Drug Administration (FDA)
clinical hold orders, which may be enforced during drug de-
velopment, if an unreasonable risk is perceived for participat-
ing subjects, revealed that, between 2008 and 2014, 29 such
holds had been actioned; seven for unexpected deaths, and
nine involving unexpected target organ damage [53]. Claims
that most drug failures are not for reasons of toxicity or effi-
cacy undetected in preclinical studies, are false [54–56].
The ethical implications of persisting with the status
quo of animal-oriented drug testing and development
are therefore clear. It is undoubtedly time for a serious,
large-scale, industry-wide consideration of the necessity
of animal drug testing, involving all the stakeholders—
regulators, scientists, politicians, developers of alterna-
tive testing methods, and so on. This must entail a crit-
ical attitude, asking what is wrong with the animal tests,
and identifying areas in which they are not performing,
instead of seeking to justify those tests by identifying
particular pharmaceutical or toxicological areas in which
they do have some human-predictive power and pas-
sively accepting that that is a sufficient justification for
their general application. This must also involve a deep
deliberation on what all the myriad alternative methods,
human, in vitro and in silico can provide when used to-
gether in intelligent strategies, which are increasingly
capable, astounding, and of course, human relevant (see,
for example, the proceedings of the 10th World Con-
gress on Alternatives and Animal Use in the Life Sci-
ences [57], and [58–61]). Instead of expecting perfection
from them, highlighting where they fall short, and apply-
ing standards of validation to them that the animal tests
have never met, and could never meet, their application
must be weighed against the ethical cost of animal test-
ing—the suffering, pain and death involved for millions
of animals every year—and the human ethical cost of de-
veloping toxic and harmful medicines, and of missing
medicines that would have been safe and effective, but
that were terminated due to serious animal toxicities
which may not have been relevant to humans.
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